Eli Lilly and Company (NYSE:LLY) is one of the 10 Best American Stocks to Buy and Hold for the Next Decade.
On May 31, 2026, Eli Lilly and Company announced results from the Phase 3 Libretto-432 clinical trial of Retevmo as adjuvant therapy versus placebo in patients with early-stage rearranged during transfection fusion-positive non-small cell lung cancer. The study met its primary endpoint, showing a “highly statistically significant and clinically meaningful” improvement in investigator-assessed event-free survival. Eli Lilly said selpercatinib reduced the risk of disease recurrence or death by 83% versus placebo in the primary analysis population.
On May 28, 2026, Eli Lilly and Company said all three of the nation’s largest pharmacy benefit managers will cover its full obesity medicine portfolio, expanding access to FDA-approved options through existing insurance. Coverage from CVS Caremark (CVS) Commercial Template begins June 1 for Foundayo, while current Zepbound patients will continue to have uninterrupted coverage and broader access across template plans by October 1. Eli Lilly said eligible commercially covered patients can access both medicines for as little as $25 per month, while Medicare Part D beneficiaries may be eligible to pay $50 per month beginning July 1 through the Medicare GLP-1 Bridge program.
Pixabay/Public Domain
On May 26, 2026, BofA raised the firm’s price target on Eli Lilly and Company to $1,251 from $1,133 and maintained a Buy rating on the shares. BofA said Lilly’s overall revenue and profit growth should be driven by a doubling of GLP-1 U.S. market sales by 2033.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products internationally.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.